Clementia Pharmaceuticals (NASDAQ: CMTA) is one of 293 public companies in the “Bio Therapeutic Drugs” industry, but how does it weigh in compared to its competitors? We will compare Clementia Pharmaceuticals to similar companies based on the strength of its analyst recommendations, institutional ownership, dividends, earnings, valuation, profitability and risk.
This is a summary of recent ratings and price targets for Clementia Pharmaceuticals and its competitors, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Clementia Pharmaceuticals Competitors||1218||3588||12109||251||2.66|
Valuation and Earnings
This table compares Clementia Pharmaceuticals and its competitors gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Clementia Pharmaceuticals||N/A||-$57.51 million||-3.14|
|Clementia Pharmaceuticals Competitors||$293.65 million||$35.70 million||71.11|
Clementia Pharmaceuticals’ competitors have higher revenue and earnings than Clementia Pharmaceuticals. Clementia Pharmaceuticals is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
Insider & Institutional Ownership
68.4% of Clementia Pharmaceuticals shares are held by institutional investors. Comparatively, 48.7% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 17.3% of shares of all “Bio Therapeutic Drugs” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
This table compares Clementia Pharmaceuticals and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Clementia Pharmaceuticals Competitors||-5,409.58%||-155.65%||-34.34%|
Clementia Pharmaceuticals Company Profile
Clementia Pharmaceuticals Inc. is a clinical stage biopharmaceutical company. The Company is engaged in developing disease-modifying treatments for patients suffering from debilitating bone and other diseases with high unmet medical need. Its lead product candidate, palovarotene, is an oral small molecule that binds and activates retinoic acid receptor gamma (an RARg agonist), and has activity in preventing abnormal new bone formation as well as scar tissue formation (or fibrosis) in a variety of tissues in animal models. It is developing palovarotene for the treatment of Fibrodysplasia Ossificans Progressiva (FOP) and Multiple Osteochondroma (MO). Its programs focus on diseases involving tissue transformation via retinoic acid receptors (RARs). The Company also has an eye drop formulation of palovarotene that can potently increase tear production and decrease corneal damage.
Receive News & Ratings for Clementia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clementia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.